Cargando…
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
BACKGROUND: Pegylated interferon alfa-2a (PEG-IFN-α-2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia (ET) and polycythemia vera (PV). We recently reported results of a phase 2 trial of...
Autores principales: | Masarova, Lucia, Yin, C. Cameron, Cortes, Jorge E., Konopleva, Marina, Borthakur, Gautam, Newberry, Kate J., Kantarjian, Hagop M., Bueso-Ramos, Carlos E., Verstovsek, Srdan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679503/ https://www.ncbi.nlm.nih.gov/pubmed/29152412 http://dx.doi.org/10.1186/s40164-017-0090-5 |
Ejemplares similares
-
Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up
por: Masarova, Lucia, et al.
Publicado: (2017) -
Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019) -
Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World
por: Sun, Yingxin, et al.
Publicado: (2021) -
P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS
por: Kuykendall, Andrew, et al.
Publicado: (2023) -
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
por: Verstovsek, Srdan, et al.
Publicado: (2023)